Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daron G Ferris

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
The New England Journal of Medicine|May 15, 2007
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseasesSuzanne M Garland, Mauricio Hernandez-Avila, Cosette M Wheeler, et al.
CA: a Cancer Journal for Clinicians|January 24, 2007
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursorsDebbie Saslow, Philip E Castle, J Thomas Cox, et al.
Lancet (London, England)|May 22, 2007
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trialsElmar A Joura, Sepp Leodolter, Mauricio Hernandez-Avila, et al.
Papillomavirus Research (Amsterdam, Netherlands)|October 28, 2017
Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by regionXavier Castellsagué, Kevin A Ault, F Xavier Bosch, et al.
International Journal of Cancer|October 16, 2010
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccineKevin A Ault, Elmar A Joura, Susanne K Kjaer, et al.
Obstetrics and Gynecology|July 12, 2018
Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of AgeSuzanne M Garland, Elmar A Joura, Kevin A Ault, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 1, 2009
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesionsSusanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, et al.
BMJ (Clinical Research Ed.)|July 22, 2010
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial, Joakim Dillner, Susanne K Kjaer, et al.
Human Vaccines|October 27, 2009
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infectionSven-Eric Olsson, Susanne K Kjaer, Kristján Sigurdsson, et al.
The Journal of Infectious Diseases|February 25, 2009
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 yearsCosette M Wheeler, Susanne K Kjaer, Kristján Sigurdsson, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
The New England Journal of Medicine|May 15, 2007
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseasesSuzanne M Garland, Mauricio Hernandez-Avila, Cosette M Wheeler, et al.
CA: a Cancer Journal for Clinicians|January 24, 2007
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursorsDebbie Saslow, Philip E Castle, J Thomas Cox, et al.
Lancet (London, England)|May 22, 2007
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trialsElmar A Joura, Sepp Leodolter, Mauricio Hernandez-Avila, et al.
Papillomavirus Research (Amsterdam, Netherlands)|October 28, 2017
Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by regionXavier Castellsagué, Kevin A Ault, F Xavier Bosch, et al.
International Journal of Cancer|October 16, 2010
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccineKevin A Ault, Elmar A Joura, Susanne K Kjaer, et al.
Obstetrics and Gynecology|July 12, 2018
Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of AgeSuzanne M Garland, Elmar A Joura, Kevin A Ault, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 1, 2009
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesionsSusanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, et al.
BMJ (Clinical Research Ed.)|July 22, 2010
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial, Joakim Dillner, Susanne K Kjaer, et al.
Human Vaccines|October 27, 2009
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infectionSven-Eric Olsson, Susanne K Kjaer, Kristján Sigurdsson, et al.
The Journal of Infectious Diseases|February 25, 2009
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 yearsCosette M Wheeler, Susanne K Kjaer, Kristján Sigurdsson, et al.
Pageof 10